Trials / Recruiting
RecruitingNCT05954897
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma: a Phase II, Single-arm, Prospective Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC | RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2026-01-01
- Completion
- 2027-01-01
- First posted
- 2023-07-20
- Last updated
- 2023-07-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05954897. Inclusion in this directory is not an endorsement.